PUBLICATIONS
Primary Articles
​Cruz LS, Robinson M, Stevenson D, Amador IC, Jordan GJ, Valencia S, Navarrete C, House CD. Chemotherapy Enriches for Proinflammatory Macrophage Phenotypes that Support Cancer Stem-Like Cells and Disease Progression in Ovarian Cancer. Cancer Res Commun. 2024 Oct 1;4(10):2638-2652. doi: 10.1158/2767-9764.CRC-24-0311
Waters JA, Robinson M, Lujano-Olazaba O, Lucht C, Gilbert SF, House CD. Omental preadolescent stimulate matrix remodeling and IGF signaling to support ovarian cancer metastasis. Cancer Res. 2024 Apr 18;84(13):2073–89. doi: 10.1158/0008-5472.CAN-23-2613. PMID: 38635891
​
Carlson N., House C.D., and Tombasco M. Toward a Transportable Cell Culture Platform for Evaluating Radiotherapy Dose Modifying Factors. International Journal of Molecular Sciences. 2023 Nov3;24(21):15953. doi: 10.3390/ijms242115953. PMID: 37958936
​
Harrington B., Kamdar R., Ning F., Korrapati S., Caminear M.W., Hernandez L.F., Butcher D., Edmondson E.F., Traficante N., Hendley J., Australian Ovarian Cancer Study, Gough M., Rogers R., Lourie R., Shetty J., Tran B., Elloumi F., Abdelmaksoud A., Lal Nag M., Mazan-Mamczarz K., House C.D., Hooper J.D., and Annunziata C.M. UGDH promotes tumor-initiating cells and a fibroinflammatory tumor microenvironment in ovarian cancer. Journal of Experimental and Clinical Cancer Research. 2023 Oct 19;42(1):270 doi: 10.1186/s13046-023-02820-z. PMID: 37858159
​
Kamdar RD, Harrington BS, Attar E, Korrapati S, Shetty J, Zhao Y, Tran B, Wong N, House CD, Annunziata CM. NF-κB Signaling Modulates miR-452-5p and miR-335-5p Expression to Functionally Decrease Epithelial Ovarian Cancer Progression in Tumor-Initiating Cells. Int J Mol Sci. 2023 Apr 25;24(9):7826. doi: 10.3390/ijms24097826. PMID: 37175530; PMCID: PMC10178396
​
Holmberg R, Robinson M, Gilbert SF, Lujano-Olazaba O, Waters JA, Kogan E, Velasquez CLR, Stevenson D, Cruz LS, Alexander LJ, Lara J, Mu EM, Camillo JR, Bitler BG, Huxford T, and House CD. TWEAK-Fn14-RelB signaling cascade promotes stem cell-like features that contribute to post-chemotherapy ovarian cancer relapse. Mol Cancer Res. 2023 Feb 1;21(2):170-186. doi: 10.1158/1541-7786.MCR-22-0486. PMID: 36214671; PMCID: PMC9890141
Robinson M, Gilbert SF, Waters JA, Lujano-Olazaba O, Lara J, Alexander LJ, Green SE, Burkeen GA, Patrus O, Sarwar Z, Holmberg R, Wang C, House CD. Characterization of SOX2, OCT4 and NANOG in Ovarian Cancer Tumor-Initiating Cells. Cancers (Basel). 2021 Jan 12;13(2):262. doi: 10.3390/cancers13020262. PMID: 33445692; PMCID: PMC7828139.
​
​Harrington BS, Ozaki MK, Caminear MW, Hernandez LF, Jordan E, Kalinowski NJ, Goldlust IS, Guha R, Ferrer M, Thomas C, Shetty J, Tran B, Wong N, House CD, and Annunziata CM. Drugs Targeting Tumor-initiating cells prolong survival in a post-surgery, post-chemotherapy ovarian cancer relapse model. Cancers (Basel). 2020 Jun 21;12(6):1645.doi:10.3390/cancers12061645
​
​
House CD, Jordan EA, Hernandez L, Ozaki M, James JM, Kim MK, Kruhlak MJ, Batchelor E, Elloumi F, Cam MC, and Annunziata CM. NF-kB promotes ovarian tumorigenesis via classical pathways supporting proliferative cancer cells and alternative pathways supporting ALDH+ cancer stem-like cells. Cancer Res. 2017;77(24):6927-40. doi:10.1158/0008-5472.CAN-17-0366
​
Kim MK, Pongas G, Min DJ, House CD, Jordan EA, Caplen N, Chakka S, Ohiri J, Kruhlak MJ, and Annunziata CM. BRD4 facilitates DNA damage response and represses CBX5/Heterochromatin protein 1 (HP1). Oncotarget. 2017 May 3;8(31):51402-51415. doi: 10.18632/oncotarget.17572
​
Kim MK, Caplen N, Chakka S, Hernandez L, House CD, Pongas G, Jordan E, Annunziata CM. Identification of therapeutic targets applicable to clinical strategies in ovarian cancer. BMC Cancer. 2016; 16:678
​
Hernandez L, Kim MK, Lyle LT, Bunch KP, House CD, Ning F, Noonan AM, and Annunziata CM. Characterization of ovarian cancer cell lines as in vivo models for preclinical studies. Gynecol Oncol. 2016:142(2): 332-40
​
House CD, Wang B, Cennicola K, Williams R, Samaan M, Olender J, Patel V, Baptista-Hon D, Annunziata CM, Gutkind JS, Hales TG, and Lee NH. Voltage-gated Na+ Channel Activity Increases Colon Cancer Transcriptional Activity and Invasion Via Persistent MAPK Signaling. Scientific Reports. 2015; 5:11541 10.1038/srep11541
​
House CD, Vaske CJ, Schwartz AM, Obias V, Frank B, Luu T, Sarvazyan N, Strausberg RL, Hales TG, Stuart JM and Lee NH. Voltage-gated Na+ channel SCN5A is a key regulator in a colon cancer invasion gene transcriptional network. Cancer Research. 2010;70(17): 6957-6967. *Article featured on issue cover
​
Zhang J, Panicker LM, Seigneur EM, Lin L, House CD, Morgan W, Chen WC, Mehta H, Haj-Ali M, Yu Z, and Simonds WF. Cytoplasmic polyadenylation element binding protein is a conserved target of tumor suppressor HRPT2/CDC73. Cell Death and Differentiation. 2010;17(10): 1551-1565
​
Vaske CJ, House CD, Frank B, Yeang CH, Lee NH and Stuart JM. A factor graph nested effects model to identify networks from genetic perturbations. PLOS Comput.Biol. 2009; 5: e1000274. PMCID:PMC2613752
​
Tapocik JD, Letwin NE, Kafkafi N, Mayo C, Frank B, Luu TV, Achinike O, House CD, Williams R, Elmer GI, and Lee NH. Identification of candidate genes and gene networks specifically associated with analgesic tolerance to morphine. J. Neurosci. 2009;29: 5295-5307
​
Lee NH, Haas BJ, Letwin NE, Frank BC, Luu TV, Sun Q, House CD, Yerga-Woolwine S, Farms P, Manickavasagam E, and Joe B. Cross-talk of expression quantitative trait loci within 2 interacting blood pressure quantitative trait loci. Hypertension. 2007;50(6): 1126-1133
​
Review and Method Articles
Waters JA, Urbano I, Robinson M, and House CD, Insulin-like growth factor binding protein 5: Diverse roles in cancer. Frontiers Oncology. Nov.17 2022
​
House CD, Hernandez L, Annunziata CM. In vitro enrichment of ovarian cancer tumor-initiating cells. JoVE. Feb. 18 2015;(96)
​
House CD, Hernandez L, Annunziata CM. Recent technological advances in using mouse models to study ovarian cancer. Frontiers Oncology. Feb 13 2014;4:26
Book Chapters
Waters JW and House CD. Ovarian Cancer Stem Cell Biology and Chemoresistance. In G. Samimi and C. Annunziata (Eds.), Overcoming Ovarian Cancer Chemoresistance (Vol. 11,1st ed. pp. 55-77)